29 citations
,
January 2016 in “CNS drugs” This review of teriflunomide for relapsing-remitting multiple sclerosis examines its clinical and safety outcomes, finding it significantly reduces relapse rates and disability progression while being generally well-tolerated.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
January 2025 in “Organics” This study found that differently charged micelles influence the acid-base equilibria of cetirizine by altering its ionization constants, indicating potential interactions with biomolecules of various charges under physiological conditions.
June 2017 in “Poster presentations” In this study, the safety profiles of four treatments for early rheumatoid arthritis were assessed over one year, and the most serious side effects necessitating treatment discontinuation were noted in the leflunomide group, whereas no such withdrawals occurred in the methotrexate plus prednisolone group.
December 2025 in “International Journal of Dermatology” This systematic review reported that while combining low-dose oral minoxidil with Janus kinase inhibitors may enhance treatment outcomes in alopecia areata, the evidence remains weak due to limited sample sizes and potential publication bias, and more rigorous trials are necessary to assess efficacy and safety.
6 citations
,
July 2015 in “JAAD Case Reports” This study describes a case of erlotinib-induced alopecia, unresponsive to traditional corticosteroid treatments, that was successfully managed with doxycycline, suggesting a novel approach for EGFR inhibitor-associated alopecia.
81 citations
,
February 2022 in “Bioactive Materials” This study reported the development of pH-responsive nanoparticles that effectively deliver vancomycin in a controlled manner, demonstrated enhanced antibacterial activity, and showed promise for clinical applications by targeting bacterial infection sites with programmable drug release.
This study found that mycophenolate mofetil was well tolerated and effective as a second-line treatment for autoimmune hepatitis in patients who were intolerant to azathioprine.
3 citations
,
January 2025 in “Journal of Natural Products” In this study, researchers isolated new compounds from the plant *Calanthe cardioglossa* and found that five of these compounds, particularly calancardin B, significantly reduced TNF-α levels in immune cells relevant to multiple sclerosis, suggesting potential for immunomodulatory effects.
February 2018 in “Biophysical Journal” This study found that cyclosporine A can alter lipid bilayer properties and does so at a slower rate, suggesting conformational shifts may facilitate its membrane crossing.
January 2015 in “프로그램북(구 초록집)” This study highlights that the combination of adapalene and benzoyl peroxide (Epiduo®) is an effective first-line treatment for acne, significantly inhibiting antibiotic-susceptible and antibiotic-resistant P. acnes strains.
April 2022 in “Reactions Weekly”
January 2024 in “Journal of Crohn's and colitis” This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.
September 2025 in “Deleted Journal” This study found that in vitro environments simulating testosterone levels in elderly males, testosterone and its metabolite DHT significantly reduced macrophages' ability to phagocytize MRSA and Pseudomonas aeruginosa, suggesting AR manipulation and inhibiting testosterone-DHT conversion might help fight wound infections in the elderly.
August 2026 in “International Journal of Dermatology” This article discusses the availability of data from TriNetX for research purposes and reports no new findings.
5 citations
,
March 2020 in “Thoracic Cancer” In this phase I study, CT-707, a new ALK inhibitor, showed a 77% response rate among Chinese patients with advanced ALK-rearranged non-small cell lung cancer, suggesting clinical effectiveness despite some adverse events like diarrhea and liver enzyme elevation.
January 1975 in “NJEA Review” This Phase II study found that BAY 43-9006, given at 400 mg orally twice daily, led to stable disease in 30% and tumor reduction in 40% of renal cell carcinoma patients.
December 2024 in “Food Bioscience” In a depilation mouse model, this study found that Limosilactobacillus fermentum MF10 promoted hair growth and increased follicle size by activating skin Wnt/β-catenin signaling and modulating gut microbiota, with effects comparable to the positive control finasteride.
October 2025 in “Journal of Molecular Structure” Hyaluronic acid microneedles help deliver minoxidil derivatives effectively for hair regrowth.
36 citations
,
March 2014 in “Annals of the Rheumatic Diseases” This study found that activating liver X receptors with an agonist reduced skin fibrosis in experimental models, particularly in inflammation-driven conditions, by inhibiting macrophage infiltration and interleukin-6 release.
3 citations
,
November 1998 in “PubMed” This study found that finasteride significantly inhibits the metabolism of tirilazad to its active metabolites without greatly affecting tirilazad's overall clearance.
February 1996 in “Clinical Pharmacology & Therapeutics” MK-386 reduces sebum DHT levels.
5 citations
,
May 2017 in “Current Opinion in Pediatrics” This review found that hormonal therapies, including FDA-approved combined oral contraceptive pills and spironolactone, are effective and well-tolerated treatments for acne vulgaris in adolescents with or without endocrine disorders, providing alternative options to antibiotics.
1 citations
,
June 2016 in “FEBS open bio” This study reports that topical fish oil treatment in GsdmA3 Dfl/+ mice increased cellular proliferation and macrophages but did not affect COX-2 expression related to psoriasis-like skin changes.
May 2025 in “Pediatric Dermatology” This systematic review identified topical and oral minoxidil as the most effective treatments for monilethrix, but noted the varying efficacy of oral retinoids and other treatments.
3 citations
,
October 1994 in “Journal of Labelled Compounds and Radiopharmaceuticals” This synthesis report details the successful development of a C-14 labeled isotopomer of LY300502, a 5α-reductase inhibitor, through a multi-step radiochemical process.
April 2023 in “Journal of Investigative Dermatology” This study found that the oral IRAK4-inhibitors BAY 1834845 and BAY 1830839 reduced skin inflammation and systemic inflammatory responses in healthy volunteers, showing similar pharmacodynamic effects to prednisolone when challenged with topical imiquimod and intravenous LPS.
39 citations
,
October 2015 in “Case Reports” In this case series, four adults developed severe, disabling multisymptom illness potentially linked to fluoroquinolone use, which persisted and progressed even after discontinuation of the drug.
This article provides an overview of the indications, interactions, and various potential adverse reactions associated with several drugs, but it reports no specific new results.
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This publication presents a library of precision geometric medicines that reportedly kill harmful bacteria and fungi while sparing beneficial organisms, using a delivery system that targets pathogens specifically and avoids ecological harm.